"I'm Not Wanting to be a Martyr”: Learning from Latina Educator Activists in Chicago Public Schools During COVID-19

I center the experiences of four Latina educators working in Chicago Public Schools (CPS) to learn about their activism amidst the early months of the COVID-19 pandemic. Through a storying methodological approach (San Pedro, Res Teach Engl 50(2):132–153, 2015;San Pedro & Kinloch, Am Educ Res J 54(15):373S–394S, 2017), this project is guided by the following research question: How were Latina educator activists organizing around justice-based issues during the pandemic? The findings of this study highlight how the lack of support and respect from CPS's top-down management approach shaped the activism participants engaged in ? particularly in their use of mutual aid to advocate for the communities they serve. Moreover, as active members of the Chicago Teachers Union, participants sustained their activism through the support they received from their union and the solidarity and joy forged with their students and each other. This study builds upon existing knowledge of Latina teacher activists by highlighting the critical role their identities, experiences, and expertise play in understanding how policy impacts them and how they shape policy through their activism.

Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.

Background: With the widespread transmission of the Omicron SARS-CoV-2 variant, reinfections have become increasingly common. Here, we explored the role of immunity, primary infection severity, and variant predominance in the risk of reinfection and severe COVID-19 during Omicron predominance in Mexico. Methods: We analyzed reinfections in Mexico in individuals with a primary infection separated by at least 90 days from reinfection using a national surveillance registry of SARS-CoV-2 cases from March 3rd, 2020, to August 13th, 2022. Immunity-generating events included primary infection, partial or complete vaccination, and booster vaccines. Reinfections were matched by age and sex with controls with primary SARS-CoV-2 infection and negative RT-PCR or antigen test at least 90 days after primary infection to explore reinfection and severe disease risk factors. We also compared the protective efficacy of heterologous and homologous vaccine boosters against reinfection. Results: We detected 231,202 SARS-CoV-2 reinfections in Mexico, most occurring in unvaccinated individuals (41.55%). Over 207,623 reinfections occurred during periods of Omicron (89.8%), BA.1 (36.74%), and BA.5 (33.67%) subvariant predominance and a case-fatality rate of 0.22%. Vaccination protected against reinfection, without significant influence of the order of immunity-generating events and provided >90% protection against severe reinfections. Heterologous booster schedules were associated with ~11% and ~ 54% lower risk for reinfection and reinfection-associated severe COVID-19, respectively, modified by time-elapsed since the last immunity-generating event, when compared against complete primary schedules. Conclusion: SARS-CoV-2 reinfections increased during Omicron predominance. Hybrid immunity provides protection against reinfection and associated severe COVID-19, with potential benefit from heterologous booster schedules.

Effects of social responsibility on legitimacy and revisit intention: The moderating role of anxiety

Companies that develop social responsibility actions gain legitimacy, which increases consumer trust and revisit intention. However, the effects of both socially responsible actions and legitimacy on customer behavior are not always direct, as they vary depending on the context. The COVID-19 pandemic has revealed a new context in which emotions play a determining role in consumer behavior. The number of people diagnosed with anxiety continues to grow worldwide, and this is known as a mental health epidemic. The aim of this research is to explore the moderating effect of anxiety on the relationships between social responsibility, legitimacy, and revisit intention. Using a sample of 1,200 supermarket buyers and applying a structural equation system, it is shown that social responsibility and legitimacy influence revisit intention, and the level of anxiety moderates these relationships. This study suggests building trust by adapting business policies to consumers' emotional backgrounds. (PsycInfo Database Record (c) 2023 APA, all rights reserved)

Is Purchase Behavior Different for Consumers with Long COVID?

COVID-19 has generated an uncertain environment, which has motivated changes in consumers' behavior globally. However, previous studies have not clarified if these effects are equally strong throughout the population. In this research, we want to analyze if there are behavioral differences between long-COVID consumers and others. For this purpose, we analyzed a sample of 522 consumers divided into three groups depending on their type of exposure to the disease: those with long COVID; ones that had recovered from COVID-19; and those that had never had COVID-19. The results show that the effect that COVID-19 has on purchase behavior differs depending on the type of exposure to the disease. In fact, those with long COVID experienced more pleasure when purchasing than other people, but they needed higher trust levels in the enterprises to purchase from them, since that reduces their perception of uncertainty. Furthermore, for long-COVID individuals, an organization's legitimacy level is even more important than for other consumer groups with less contact with the disease.

Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.

OBJECTIVES: Vaccination has been effective in ameliorating the impact of COVID-19. Here, we report vaccine effectiveness (VE) of the nationally available COVID-19 vaccines in Mexico. METHODS: Retrospective analysis of a COVID-19 surveillance system to assess the VE of the BNT162b2, messenger RNA (mRNA)-12732, Gam-COVID-Vac, Ad5-nCoV, Ad26.COV2.S, ChAdOx1, and CoronaVac vaccines against SARS-CoV-2 infection, COVID-19 hospitalization, and death in Mexico. The VE was estimated using time-varying Cox proportional hazard models in vaccinated and unvaccinated adults, adjusted for age, sex, and comorbidities. VE was also estimated for adults with diabetes, aged ≥60 years, and comparing the predominance of SARS-CoV-2 variants B.1.1.519 and B.1.617.2. RESULTS: We assessed 793,487 vaccinated and 4,792,338 unvaccinated adults between December 24, 2020 and September 27, 2021. The VE against SARS-CoV-2 infection was the highest for fully vaccinated individuals with mRNA-12732 (91.5%, 95% confidence interval [CI] 90.3-92.4) and Ad26.COV2.S (82.2%, 95% CI 81.4-82.9); for COVID-19 hospitalization, BNT162b2 (84.3%, 95% CI 83.6-84.9) and Gam-COVID-Vac (81.4% 95% CI 79.5-83.1), and for mortality, BNT162b2 (89.8%, 95% CI 89.2-90.2) and mRNA-12732 (93.5%, 95% CI 86.0-97.0). The VE decreased for all vaccines in adults aged ≥60 years, people with diabetes, and periods of Delta variant predominance. CONCLUSION: All the vaccines implemented in Mexico were effective against SARS-CoV-2 infection, COVID-19 hospitalization, and death. Mass vaccination with multiple vaccines is useful to maximize vaccination coverage.

Monitoring and Tracking the Spread of SARS-CoV-2 in Asturias, Spain

Mutational analysis of SARS-CoV-2 can quantify their relative importance over time, enable the dominant mutations to be identified and facilitate near real-time detection, comparison, and tracking of evolving variants. Collected samples in Asturias an autonomous community of Spain with a large aged population, and high levels of migration and tourism was monitored and tracked from its beginning in February 2020 until its decline and stabilization in August 2021, were characterized using whole genomic sequence and single nucleotide polymorphism. Data held in the GISAID database was analyzed to establish patterns in the appearance and persistence of SARS-CoV-2 strains. Only 138 non-synonymous mutations occurring in more than 1% of the population of SARS-CoV-2 were found, identifying 10 major variants worldwide (7 arose before January 2021), 19 regional and 1 local. In Asturias only 17 different variants were found. After vaccination, no further regional majority variants were found. Only half of the defined variants circulated and no new variants were generated, indicating that infection control measures (fast diagnosis, prevention measures and vaccination) were efficient.

Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.

BACKGROUND: In 2021, we showed an increased risk associated with COVID-19 in pregnancy. Since then, the SARS-CoV-2 virus has undergone genetic mutations. We aimed to examine the effects on maternal and perinatal outcomes of COVID-19 during pregnancy, and evaluate vaccine effectiveness, when omicron (B.1.1.529) was the variant of concern. METHODS: INTERCOVID-2022 is a large, prospective, observational study, involving 41 hospitals across 18 countries. Each woman with real-time PCR or rapid test, laboratory-confirmed COVID-19 in pregnancy was compared with two unmatched women without a COVID-19 diagnosis who were recruited concomitantly and consecutively in pregnancy or at delivery. Mother and neonate dyads were followed until hospital discharge. Primary outcomes were maternal morbidity and mortality index (MMMI), severe neonatal morbidity index (SNMI), and severe perinatal morbidity and mortality index (SPMMI). Vaccine effectiveness was estimated, adjusted by maternal risk profile. FINDINGS: We enrolled 4618 pregnant women from Nov 27, 2021 (the day after WHO declared omicron a variant of concern), to June 30, 2022: 1545 (33%) women had a COVID-19 diagnosis (median gestation 36·7 weeks [IQR 29·0-38·9]) and 3073 (67%) women, with similar demographic characteristics, did not have a COVID-19 diagnosis. Overall, women with a diagnosis had an increased risk for MMMI (relative risk [RR] 1·16 [95% CI 1·03-1·31]) and SPMMI (RR 1·21 [95% CI 1·00-1·46]). Women with a diagnosis, compared with those without a diagnosis, also had increased risks of SNMI (RR 1·23 [95% CI 0·88-1·71]), although the lower bounds of the 95% CI crossed unity. Unvaccinated women with a COVID-19 diagnosis had a greater risk of MMMI (RR 1·36 [95% CI 1·12-1·65]). Severe COVID-19 symptoms in the total sample increased the risk of severe maternal complications (RR 2·51 [95% CI 1·84-3·43]), perinatal complications (RR 1·84 [95% CI 1·02-3·34]), and referral, intensive care unit (ICU) admission, or death (RR 11·83 [95% CI 6·67-20·97]). Severe COVID-19 symptoms in unvaccinated women increased the risk of MMMI (RR 2·88 [95% CI 2·02-4·12]) and referral, ICU admission, or death (RR 20·82 [95% CI 10·44-41·54]). 2886 (63%) of 4618 total participants had at least a single dose of any vaccine, and 2476 (54%) of 4618 had either complete or booster doses. Vaccine effectiveness (all vaccines combined) for severe complications of COVID-19 for all women with a complete regimen was 48% (95% CI 22-65) and 76% (47-89) after a booster dose. For women with a COVID-19 diagnosis, vaccine effectiveness of all vaccines combined for women with a complete regimen was 74% (95% CI 48-87) and 91% (65-98) after a booster dose. INTERPRETATION: COVID-19 in pregnancy, during the first 6 months of omicron as the variant of concern, was associated with increased risk of severe maternal morbidity and mortality, especially among symptomatic and unvaccinated women. Women with complete or boosted vaccine doses had reduced risk for severe symptoms, complications, and death. Vaccination coverage among pregnant women remains a priority. FUNDING: None.

Effects of social responsibility on legitimacy and revisit intention: The moderating role of anxiety

Companies that develop social responsibility actions gain legitimacy, which increases consumer trust and revisit intention. However, the effects of both socially responsible actions and legitimacy on customer behavior are not always direct, as they vary depending on the context. The COVID-19 pandemic has revealed a new context in which emotions play a determining role in consumer behavior. The number of people diagnosed with anxiety continues to grow worldwide, and this is known as a mental health epidemic. The aim of this research is to explore the moderating effect of anxiety on the relationships between social responsibility, legitimacy, and revisit intention. Using a sample of 1,200 supermarket buyers and applying a structural equation system, it is shown that social responsibility and legitimacy influence revisit intention, and the level of anxiety moderates these relationships. This study suggests building trust by adapting business policies to consumerś emotional backgrounds.

Low-dose Radiation Therapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial.

BACKGROUND AND PURPOSE: To evaluate the results of low-dose radiation therapy (LD-RT) to lungs in the management of patients with COVID-19 pneumonia. MATERIAL AND METHODS: We conducted a prospective phase I-II trial enrolling COVID-19 patients ≥50 years-old, with bilateral lung involvement at imaging study and oxygen requirement (oxygen saturation ≤93% on room air). Patients received 1 Gy to whole lungs in a single fraction. Primary outcome was a radiological response assessed as severity and extension scores at days +3 and +7. Secondary outcomes were toxicity (CTCAE v5.0), days of hospitalization, changes in inflammatory blood parameters (ferritin, lymphocytes, C-reactive protein, d-dimer and LDH) and SatO2/FiO2 index (SAFI), at day +3 and +7. Descriptive analyses were summarized as means with standard deviation (SD) and/or medians with interquartile ranges (IQR). A Wilcoxon sign rank test for paired data was used to assess the CT scores and Chi Square was used to assess for comparison of categorical variables. RESULTS: Forty-one patients were included. Median age was 71 (IQR 60-84). Eighteen patients (44%) previously received an anti-COVID treatment (tocilizumab, lopinavir/ritonavir, remdesivir) and thirty-two patients (84%) received steroids during LD-RT. The extension score improved significantly (p = 0.02) on day +7. Mean baseline extension score was 13.7 (SD ± 4.9) with a score of 12.2 (±5.2) at day 3, and 12.4 ± 4.7 at day 7. No differences were found in the severity score. SAFI improved significantly on day +3 and +7 (p < 0.01). Median SAFI on day 0 was 147 (IQR 118-264), 230 (IQR 120-343) on day +3 and 293 (IQR 121-353) on day +7. Significant decrease was found in C-reactive protein on day +7 (p = 0.02) and in lymphocytes counts on day +3 and +7 (p = 0.02). The median number of days in hospital after RT was 11 (range 4-78). With a median follow-up of 60 days after LD-RT, 26 (63%) patients were discharged, 11 (27%) died because of COVID respiratory failure and 4 (10%) died of other causes. CONCLUSIONS: LD-RT is a feasible and well-tolerated treatment that could lead to rapid clinical improvement. Large randomized trials would be required to establish the efficacy of LD-RT to treat COVID-19 pneumonia.

Neuropsychological profile of entrepreneurs

PurposeBy analyzing variables from the fields of business and neuropsychology, this document examines alternative combinations of behavioral economics and neuropsychological characteristics that would explain a successful entrepreneurial profile.Design/methodology/approachThe research is based on information gathered through a survey of 1,080 entrepreneurs. The findings offer interesting perspectives for academics, professionals and government institutions, which illustrate various neuropsychological characteristics that a person must have to be a successful entrepreneur. The method consists of a novel perspective that integrates qualitative comparative analysis (QCAs), a method based on Boolean algebra that offers a study from a configurational perspective.FindingsFrom the mixture of configurations, the paper explores following possible traits of an entrepreneurial mindset: cognitive flexibility, risk-taking, decision-making and teamwork.Originality/valueThis paper contributes to the literature on emerging attempts and approaches to understand the entrepreneurial mindset and the possible skillset that underpins successful entrepreneurship.

Organizational legitimacy perception: Gender and uncertainty as bias for evaluation criteria

The perception of organizational legitimacy is influenced by different factors at the micro and macro levels. Organizational approval and support depend on the judgment criteria applied by the involved stakeholders. This research aims to analyze how legitimation criteria affect the different types of organizational legitimacy. Specifically, we analyze how legitimacy perception is influenced by individuals’ gender in an uncertain crisis environment, considering gender and uncertainty as the main variables. Our research was carried out in a global context of uncertainty generated by the COVID-19 pandemic. The results of the study confirm that gender and uncertainty play a relevant role in the legitimacy evaluation process. Men and women use different mindsets when evaluating organizations’ legitimacy. In a context of uncertainty, men’s legitimacy evaluation is mainly based on cognitive criteria, while women are moved by pragmatic criteria. The study provides relevant contributions, both theoretical and practical, to legitimacy theory, strategic management, gender studies and marketing and communication fields, providing insights for customizing organizational legitimation strategies taking into consideration the audience’s characteristics and environment.

Registro Argentino de manifestaciones neurológicas por coronavirus-19 (COVID-19)

Resumen La enfermedad por COVID-19 se ha extendido por el mundo desde diciembre de 2019. Los síntomas neurológicos forman parte de su espectro clínico. Objetivo: Conocer las manifestaciones neurológicas en pacientes infectados por COVID-19 en Argentina. Métodos: Estudio multicéntrico realizado en adultos, desde mayo de 2020 a enero de 2021, con COVID-19 confirmado y síntomas neurológicos. Se consignaron variables demográficas, existencia de comorbilidades sistémicas o neurológicas, la forma de comienzo de la infección, alteración en estudios complementarios y el grado de severidad de los síntomas neurológicos. Resultados: Se incluyeron 817 pacientes de todo el país, 52% varones, edad promedio 38 años. La mayoría sin comorbilidades ni patología neurológica previa. El primer síntoma de la infección fue neurológico en 56,2 % de los casos, predominando la cefalea (69%), luego anosmia/ageusia (66%). También se reportaron mialgias (52%), alodinia/ hiperalgesia (18%), astenia (6%). Un 3,2% mostró compromiso difuso del SNC como encefalopatía o convulsiones. Un 1,7% tuvo complicaciones cerebrovasculares. Los trastornos del sueño se observaron en 3,2%. Se reportaron 6 pacientes con Guillain Barré (GBS), neuropatía periférica (3,4%), parestesias en lengua (0,6%), hipoacusia (0,4%), plexopatía (0,3%). La severidad de síntomas neurológicos se correlacionó con la edad y la existencia de comorbilidades. Conclusiones: Nuestros resultados, similares a los de otros países, muestran dos tipos de síntomas neurológicos asociados a COVID-19: algunos potencialmente incapacitantes o mortales como el GBS o la encefalitis, y otros menos devastadores, pero más frecuentes como cefalea o anosmia que demandan en forma creciente atención a largo plazo. COVID-19 disease has spread around the world since December 2019. Neurological symptoms are part of its clinical spectrum. Objective: To know the neurological manifestations in patients infected by COVID-19 in Argentina. Methods: Multicenter study conducted in adults, from May 2020 to January 2021, with confirmed COVID-19 and neurological symptoms. Demographic variables, existence of systemic or neurological comorbidities, the form of onset of the infection, alteration in complementary studies and the degree of severity of neurological symptoms were recorded. Results: 817 patients from all over the country were included, 52% male, mean age 38 years, most of them without comorbidities or previous neurological pathology. The first symptom of the infection was neurological in 56.2% of the cases, predominantly headache (69%), then anosmia / ageusia (66%). Myalgias (52%), allodynia / hyperalgesia (18%), and asthenia (6%) were also reported. 3.2% showed diffuse CNS involvement such as encephalopathy or seizures. 1.7% had cerebrovascular complications. Sleep disorders were observed in 3.2%. 6 patients were reported with Guillain Barré (GBS), peripheral neuropathy (3.4%), tongue paresthesia (0.6%), hearing loss (0.4%), plexopathy (0.3%). The severity of neurological symptoms was correlated with age and the existence of comorbidities. Conclusions: Our results, similar to those of other countries, show two types of neurological symptoms associated with COVID-19: some potentially disabling or fatal such as GBS or encephalitis, and others less devastating, but more frequent such as headache or anosmia that demand increasingly long-term care.

Low-Dose Radiation Therapy in the Management of Coronavirus Disease 2019 (COVID-19) Pneumonia (LOWRAD-Cov19): Preliminary Report.

PURPOSE: Low-dose radiation therapy (LD-RT) has been shown to have an anti-inflammatory effect, and preliminary results suggest it is feasible to treat patients with coronavirus disease 2019 (COVID-19) pneumonia. MATERIALS AND METHODS: We conducted a prospective, single-arm, phase 1/2 clinical trial enrolling patients aged ≥50 years, who were coronavirus disease 2019 (COVID-19) positive, at phase 2 or 3 with lung involvement at imaging study and oxygen requirement. Patients received 100 cGy to total lungs in a single fraction. Primary outcome was radiologic response using severity and extension score on baseline computed tomography (CT), at days 3 and 7 after LD-RT. Secondary outcomes were toxicity using Common Terminology Criteria for Adverse Events v.5.0, duration of hospitalization, blood work evolution, and oxygen requirements using SatO2/FiO2 index (SAFI), at days 3 and 7 after LD-RT. RESULTS: Nine patients were included. Median age was 66 (interquartile range, 57-77). Severity score was stable or decreased in the third CT but was not statistically significant (P = .28); however, there were statistically significant changes in the extension score (P = .03). SAFI index significantly improved 72 hours and 1 week after LD-RT (P = .01). Inflammatory blood parameters decreased 1 week after RT compared with baseline; only lactate dehydrogenase decreased significantly (P = .04). Two patients presented grade 2 lymphopenia after RT and another (with baseline grade 3) worsened to grade 4. Overall, the median number of days of hospitalization was 59 (range, 26-151). After RT the median number of days in the hospital was 13 (range, 4-77). With a median follow-up after RT of 112 days (range, 105-150), 7 patients were discharged and 2 patients died, 1 due to sepsis and the other with severe baseline chronic obstructive pulmonary disease from COVID-19 pneumonia. CONCLUSIONS: Our preliminary results show that LD-RT was a feasible and well-tolerated treatment, with potential clinical improvement. Randomized trials are needed to establish whether LD-RT improves severe pneumonia.